Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06594679
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-19
Brief Title:
A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer NICHOL TRIAL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer a Single Center Open Label Single Arm Phase IbII Trial NICHOL TRIAL
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NICHOL
Brief Summary:
This is an interventional trial The goal of this clinical trial is dose finding There are two phases phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer
Target population will be patients woman age 18 years with epithelial ovarian fallopian tube or peritoneal cancer treated with at least 2 lines of therapy
Target population will be patients woman age 18 years with epithelial ovarian fallopian tube or peritoneal cancer treated with at least 2 lines of therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None